S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.09%) 40 140 points
Nasdaq Futures
(-0.05%) 18 465 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.16%) $0.928
USD/NOK
(0.33%) $10.88
USD/GBP
(0.01%) $0.792
USD/RUB
(0.03%) $92.60

Realtime updates for Benitec Biopharma Inc [BNTC]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Last Updated28 Mar 2024 @ 16:00

2.14% $ 5.25

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302
Profile picture for Benitec Biopharma Inc

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions...

Stats
Today's Volume 21 069.00
Average Volume 14 765.00
Market Cap 13.61M
EPS $0 ( 2024-02-12 )
Next earnings date ( $-0.780 ) 2024-05-13
Last Dividend $0.0450 ( 2018-06-01 )
Next Dividend $0 ( N/A )
P/E -0.0200
ATR14 $0.0650 (1.24%)
Insider Trading
Date Person Action Amount type
2024-03-06 Banks Jerel A. Buy 466 554 Options (right to buy)
2024-03-06 Boston Megan Buy 200 004 Options (right to buy)
2023-12-06 Smith Edward F Buy 35 000 Options (right to buy)
2023-12-06 Francis Peter Buy 35 000 Options (right to buy)
2023-12-06 Buchi J Kevin Buy 35 000 Options (right to buy)
INSIDER POWER
100.00
Last 38 transactions
Buy: 2 361 696 | Sell: 57 465

Benitec Biopharma Inc Correlation

10 Most Positive Correlations
RNLX0.862
TTSH0.842
BAFN0.831
OVLY0.829
VIOT0.826
GGAL0.826
ASLE0.824
CASH0.823
BOOM0.82
TELA0.818
10 Most Negative Correlations
MBCN-0.811

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Benitec Biopharma Inc Financials

Annual 2023
Revenue: $75 000.00
Gross Profit: $-306 000 (-408.00 %)
EPS: $-14.12
Q4 2023
Revenue: $7 000.00
Gross Profit: $-77 000.00 (-1 100.00 %)
EPS: $-2.83
Q3 2023
Revenue: $54 000.00
Gross Profit: $22 000.00 (40.74 %)
EPS: $-2.71
Q2 2023
Revenue: $14 000.00
Gross Profit: $-27 000.00 (-192.86 %)
EPS: $-3.27

Financial Reports:

No articles found.

Benitec Biopharma Inc Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Benitec Biopharma Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future
Information
First Dividend $0.0450 2018-06-01
Last Dividend $0.0450 2018-06-01
Next Dividend $0 N/A
Payout Date 2018-06-08
Next Payout Date N/A
# dividends 1 --
Total Paid Out $0.0450 --
Avg. Dividend % Per Year 0.00% --
Score 0.01 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
(2024-03-29)
$0 Estimate 0.00 %
Dividend Stability
0.01 Very Bad
Dividend Score
0.01
Pay Frequency
Insufficient data to determine frequency
Yearly Payout
Year Amount Yield
2018 $0.0450 0.01%
2019 $0 0.00%
2020 $0 0.00%
2021 $0 0.00%
2022 $0 0.00%
2023 $0 0.00%
2024 $0 0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
OXLC Dividend Royal 2023-12-14 Monthly 14 10.00% 8.50
QYLD Dividend Royal 2023-11-20 Monthly 11 7.50% 8.50
PSEC Dividend Royal 2023-12-26 Monthly 21 7.04% 8.50
SLVO Dividend Royal 2023-11-20 Monthly 12 10.77% 8.50
OXSQ Dividend Diamond 2023-12-14 Monthly 21 9.10% 8.50
GAIN Dividend Royal 2023-12-04 Monthly 20 8.19% 8.50
GLDI Dividend Royal 2023-11-20 Monthly 12 7.15% 8.50
HRZN Dividend King 2023-12-18 Monthly 15 6.60% 8.45
USOI Dividend Royal 2023-11-20 Monthly 8 16.70% 8.28
PFLT Dividend King 2023-11-15 Monthly 14 6.50% 8.27

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM-358.571.500-10.00-10.00[0 - 0.5]
returnOnAssetsTTM-1.0241.200-10.00-10.00[0 - 0.3]
returnOnEquityTTM-2.051.500-10.00-10.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM3.620.80010.008.00[1 - 3]
quickRatioTTM3.550.80010.008.00[0.8 - 2.5]
cashRatioTTM3.551.50010.0010.00[0.2 - 2]
debtRatioTTM0.0198-1.5009.67-10.00[0 - 0.6]
interestCoverageTTM-1 446.131.000-10.00-10.00[3 - 30]
operatingCashFlowPerShareTTM-7.012.00-2.34-4.67[0 - 30]
freeCashFlowPerShareTTM-7.012.00-3.51-7.01[0 - 20]
debtEquityRatioTTM0.0273-1.5009.89-10.00[0 - 2.5]
grossProfitMarginTTM0.8201.00010.0010.00[0.2 - 0.8]
operatingProfitMarginTTM-355.611.000-10.00-10.00[0.1 - 0.6]
cashFlowToDebtRatioTTM-42.711.000-10.00-10.00[0.2 - 2]
assetTurnoverTTM0.002860.800-3.31-2.65[0.5 - 2]
Total Score-1.934

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-0.6041.000-0.1620[1 - 100]
returnOnEquityTTM-2.052.50-10.00-10.00[0.1 - 1.5]
freeCashFlowPerShareTTM-7.012.00-2.34-7.01[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-7.012.00-2.34-4.67[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.001761.500-3.320[0.5 - 2]
operatingCashFlowSalesRatioTTM-296.161.000-10.000[0.1 - 0.5]
Total Score-3.45

Benitec Biopharma Inc

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators